University Multiprofile Hospital For Active Treatment Saint Georgi EAD
- Address
- lock Available on a paid plan
University Multiprofile Hospital For Active Treatment Saint Georgi EAD
The University Multiprofile Hospital For Active Treatment Saint Georgi EAD is a comprehensive academic medical center conducting a diverse portfolio of international clinical research across multiple therapeutic areas. The center demonstrates particular strength in hematologic malignancies and cardiovascular medicine, while maintaining active programs in metabolic disorders, autoimmune conditions, and respiratory diseases.
- Hematology and Oncology: Multiple myeloma, myeloproliferative neoplasms (myelofibrosis, polycythemia vera), chronic and acute leukemias, and various lymphomas including diffuse large B-cell lymphoma and chronic lymphocytic leukemia
- Cardiovascular and Renal Medicine: Heart failure with preserved and reduced ejection fraction, pulmonary hypertension, chronic kidney disease, and atherosclerotic cardiovascular disease in dialysis patients
- Immunology and Rheumatology: Psoriatic arthritis, juvenile idiopathic arthritis, chronic urticaria, primary immune thrombocytopenia, and multiple sclerosis
- Endocrinology and Metabolic Disorders: Type 2 diabetes with diabetic retinopathy, hypercholesterolemia, Cushing's syndrome, and pediatric growth disorders
The hospital's research capabilities extend to specialized areas including rare hematologic disorders such as thalassemia and hemophilia, infectious diseases including complicated urinary tract infections and acute respiratory distress syndrome, and pediatric conditions ranging from insomnia to systemic juvenile idiopathic arthritis. The center actively participates in early-phase through Phase 3 trials, demonstrating expertise in pharmacokinetic studies, dose-finding investigations, and large-scale international comparative effectiveness trials across both adult and pediatric populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 25 therapeutic areas and 15 of 278 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 261 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 57 by active trials.
- 1AstraZeneca AB7active
lock +56 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S14trials
lock +30 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Multiprofile Hospital For Active Treatment Saint Georgi EAD
lock Showing 1 of 194 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 278 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 7 | Unknown | 2019-03-22 | 2025-10-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.